Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Uniqure France currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between distinct art units, indicating that the applications cover different technical niches within the biotech field. Each of the 2 pending actions is assigned to one of 2 distinct examiners, resulting in an even ratio of actions to examiners.
CELINE X QIAN is the busiest examiner for the company, currently overseeing 1 pending office action. This single action represents a portion of the workload. With 2 distinct art units involved, the prosecution strategy must be tailored to the specific standards of each unit, even though the total volume of pending office actions is low.
The distribution across distinct examiners and art units ensures that no single individual or unit has a dominant influence over the portfolio. This structure requires the company to manage different sets of examination guidelines while resolving the 2 pending actions. Success in the Biotechnology & Pharmaceuticals sector will depend on addressing the unique requirements of the assigned examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18154241 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | CHONG, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18154241 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | CHONG, KIMBERLY | 1636 | §112 | Final Rejection | — | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniqure France has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kimberly Chong has the most, with 1 of Uniqure France's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
